
Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
Facilitating Neuroplastic Changes of Acute Stroke Survivors
University of Maryland, Baltimore
Stroke
This project will develop a wearable rehabilitation robot suitable for in-bed acute stage
rehabilitation. It involves robot-guided motor relearning, passive and active
motor-sensory rehabilitation early in the acute stage post-stroke including patients who
are paralyzed with no motor output. The ea1 expand
This project will develop a wearable rehabilitation robot suitable for in-bed acute stage rehabilitation. It involves robot-guided motor relearning, passive and active motor-sensory rehabilitation early in the acute stage post-stroke including patients who are paralyzed with no motor output. The early acute stroke rehabilitation device will be evaluated in this clinical trial. Type: Interventional Start Date: Jun 2025 |
|
Targeting Emotion Dysregulation to Reduce Suicide in People With Psychosis
University of Maryland, Baltimore
Psychosis
Suicide
People with psychotic disorders are excluded from most suicide-focused clinical trials
despite incredibly high rates of completed suicide, and interventions that have been
tested for this population have shown limited impact on suicide. Emotion dysregulation is
a significant suicidogenic factor tha1 expand
People with psychotic disorders are excluded from most suicide-focused clinical trials despite incredibly high rates of completed suicide, and interventions that have been tested for this population have shown limited impact on suicide. Emotion dysregulation is a significant suicidogenic factor that is understudied in people with psychotic disorders. The investigators propose to implement and evaluate an intervention targeting emotion dysregulation in people with psychotic disorders while employing rigorous statistical modeling and measurement techniques including Ecological Momentary Assessment, which will support future advanced research on suicide and suicide prevention for this high-risk group. Type: Interventional Start Date: Dec 2022 |
|
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Dennis M. McNamara, MD, MS
Peripartum Cardiomyopathy, Postpartum
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5
months postpartum in a randomized placebo controlled trial of bromocriptine therapy to
evaluate its impact on myocardial recovery and clinical outcomes. Given that
bromocriptine prevents breastfeeding, an additi1 expand
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort. Type: Interventional Start Date: Jul 2022 |
|
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
Temple University
COPD
Parallel-group, prospective, randomized, controlled phase III trial of home High flow
Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical
care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients
with moderate to very severe COPD at1 expand
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks. Type: Interventional Start Date: Feb 2022 |